Investor
The MobiHealthNews team breaks down the week's big digital health news: Teladoc's proposed $18 billion acquisition of Livongo.
Also: Dexcom continues to make strides, while iRhythm Technologies takes a hit in Q2.
The new round was led by European Bank for Reconstruction and Development and Health Capital.
The company said its services are accessible to millions of people through partnerships with over 200 employers, health plans and other strategic partners.
The deal is valued at roughly $4.7 billion.
The company's complete blood count analyzer uses artificial intelligence to quickly measure biomarkers from a fingerstick or venous sample.
Each Livongo share will be converted Teladoc stock at a 0.5920 exchange rate, plus an additional $11.44 in cash per stock.
The listing could happen either later this year or in early 2021, Reuters reports.
A majority of femtech funding goes towards fertility, pregnancy or motherhood, leaving many other women’s health areas underserved, according to Rock Health.
The regulator said it was not satisfied with Google's offer to silo Fitbit-collected data so that it could not be used for advertising purposes.